FDA Brief

Warning letters Drugs

FDA warning letter to

Walgreen Company

LowIssued Sep 12, 2023Posted Sep 19, 2023Center for Drug Evaluation and Research | CDER

FDA warns Walgreen Company that its Walgreens Sensitive Extra Whitening drug listing is incomplete and inaccurate.

What happened

FDA reviewed the electronic Drug Registration and Listing System (eDRLS) listing for Walgreens Sensitive Extra Whitening, NDC 0363-1588, after earlier deficiency and data-removal notices. It found that the labeling listed potassium nitrate and sodium fluoride as active ingredients, but the electronic listing file in Structured Product Labeling (SPL) listed only sodium fluoride. It also found that the fluoride ion strength in SPL, 0.24 g in 100 g, did not match the labeling strength of 0.15 gm in 100 gm.

What FDA found

  1. The electronic drug listing omitted potassium nitrate, an active ingredient named in the product labeling.

    Section 510(j)(1)(C) of the FD&C Act, 21 U.S.C. 360(j)(1)(c), and 21 CFR 207.49(a)(4)
  2. The fluoride ion strength in the electronic listing was 0.24 g in 100 g, but the labeling stated 0.15 gm in 100 gm.

    Section 510(j)(1)(C) of the FD&C Act, 21 U.S.C. 360(j)(1)(c), and 21 CFR 207.49(a)(4)
  3. Because the drug was not properly listed with FDA, it was misbranded.

    Section 502(o) of the FD&C Act, 21 U.S.C. 352(o)
  4. Failing to meet the drug listing requirements is a prohibited act.

    Section 301(p) of the FD&C Act, 21 U.S.C. 331(p)

What FDA wants

FDA asks the firm to notify it in writing within 15 working days of the steps taken to correct the listing violations, explain how recurrence will be prevented, and provide related documentation. If corrections cannot be completed in that time, the firm must state the reason and the time needed.

Who should pay attention

  • retailers with private-label OTC drug products
  • companies responsible for FDA drug listing and SPL submissions
  • users of FDA NDC Directory and drug listing data

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Chongqing Qiancan Technology Co., Ltd.

    Chongqing Qiancan Technology, an API maker in China, refused FDA records requests; FDA placed its drugs on import alert 66-79.

    High risk
  2. Tianjin Healthcare Medical Technology Co., Ltd.

    Chinese API maker refused FDA records requests, and all its drugs now face a US import alert.

    High risk
  3. PReye, LLC

    FDA warned PReye, LLC that its unapproved eye drop PReye Vitamin SEE was made without sterile controls in an unclassified office.

    High risk
  4. Suretec Innovations, LLC

    Suretec Innovations failed manufacturing quality rules for OTC sanitizing wipes and did not list a private-label wipe.

    High risk